Heat Biologics to Present at the 2018 BIO International Convention

DURHAM, NC / ACCESSWIRE / May 30, 2018 / Heat Biologics, Inc. HTBX, a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced its Chief Executive Officer, Jeff Wolf, will present a
corporate overview at the 2018 BIO International Convention on Wednesday, June 6th, at 2:45 PM, Eastern Time, held at the Boston Convention and Exhibition Center in Boston, MA.

The BIO International Convention allows for public and private companies to provide formal presentations, request face-to-face meetings with biotech investors and executives, attend educational sessions and engage in networking opportunities. For more information, please visit: http://convention.bio.org/about-bio-convention/.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. We also have numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!